Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
Table 5
Association of 17βHSD-1 promoter methylation with mitosis, immunohistochemistry, and molecular subtype of breast cancer.
Overall ()
%
17βHSD-1 methylation in normal tissues
17βHSD-1 methylation in cancer tissues
Methylated (38)
Unmethylated (2)
value
Methylated (39)
Unmethylated (1)
value
Freq.
(%)
Freq.
(%)
Freq.
(%)
Freq.
(%)
Mitosis:
0
4
10.0%
4
(10.5)
0
(0.0)
0.850
4
(10.3)
0
(0.0)
1.000
1
5
12.5%
5
(13.2)
0
(0.0)
5
(12.8)
0
(0.0)
2
29
72.5%
27
(71.1)
2
(100.0)
28
(71.8)
1
(100.0)
3
2
5.0%
2
(5.3)
0
(0.0)
2
(5.1)
0
(0.0)
Estrogen receptor:
Positive
27
67.5%
25
(65.8)
2
(100.0)
0.602
26
(66.7)
1
(100.0)
1.000
Negative
7
17.5%
7
(18.4)
0
(0.0)
7
(17.9)
0
(0.0)
No available data
6
15.0%
6
(15.8)
0
(0.0)
6
(15.4)
0
(0.0)
Progesterone receptor:
Positive
25
62.5%
23
(60.5)
2
(100.0)
0.532
25
(64.1)
0
(0.0)
0.375
Negative
9
22.5%
9
(23.7)
0
(0.0)
8
(20.5)
1
(100.0)
No available data
6
15.0%
6
(15.8)
0
(0.0)
6
(15.4)
0
(0.0)
Her2:
Positive
10
25.0%
10
(26.3)
0
(0.0)
0.312
10
(25.6)
0
(0.0)
1.000
Negative
19
47.5%
17
(44.7)
2
(100.0)
18
(46.2)
1
(100.0)
No available data
11
27.5%
11
(29.0)
0
(0.0)
11
(28.2)
0
(0.0)
Molecular subtype:
Luminal A
13
32.5%
11
(28.9)
2
(100.0)
0.120
13
(32.5)
0
(0.0)
0.174
Luminal B
9
22.5%
9
(23.7)
0
(0.0)
9
(22.5)
0
(0.0)
Basal-like
2
5.0%
2
(5.3)
0
(0.0)
2
(5.1)
0
(0.0)
Her2
1
2.5%
1
(2.6)
0
(0.0)
1
(2.6)
0
(0.0)
Others
8
20.0%
8
(21.1)
0
(0.0)
7
(17.9)
1
(100.0)
No available data
7
17.5%
7
(18.4)
0
(0.0)
7
(17.9)
0
(0.0)
Chi-square exact test is statistically significant at 95% confidence level.
